207 related articles for article (PubMed ID: 21848808)
1. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
Seo S; Nakamoto T; Takeshita M; Lu J; Sato T; Suzuki T; Kamikubo Y; Ichikawa M; Noda M; Ogawa S; Honda H; Oda H; Kurokawa M
Cancer Sci; 2011 Dec; 102(12):2109-17. PubMed ID: 21848808
[TBL] [Abstract][Full Text] [Related]
2. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
3. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
5. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
[TBL] [Abstract][Full Text] [Related]
6. Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia.
Yasuda T; Shirakata M; Iwama A; Ishii A; Ebihara Y; Osawa M; Honda K; Shinohara H; Sudo K; Tsuji K; Nakauchi H; Iwakura Y; Hirai H; Oda H; Yamamoto T; Yamanashi Y
J Exp Med; 2004 Dec; 200(12):1681-7. PubMed ID: 15611294
[TBL] [Abstract][Full Text] [Related]
7. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
8. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Okuda K; Golub TR; Gilliland DG; Griffin JD
Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
[TBL] [Abstract][Full Text] [Related]
9. Detection of P210bcr-abl in mature granulocytes from Ph1-positive chronic myelogenous leukemia patients by an immunoblotting method.
Kuwao F; Takahashi I
Leukemia; 1993 Aug; 7(8):1168-73. PubMed ID: 8350617
[TBL] [Abstract][Full Text] [Related]
10. Establishment, characterization, and chromosomal analysis of new leukemic cell lines derived from MT/p210bcr/abl transgenic mice.
Honda H; Ohno S; Takahashi T; Takatoku M; Yazaki Y; Hirai H
Exp Hematol; 1998 Mar; 26(3):188-97. PubMed ID: 9502614
[TBL] [Abstract][Full Text] [Related]
11. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
12. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
13. Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model.
Nagamachi A; Yamasaki N; Miyazaki K; Oda H; Miyazaki M; Honda Z; Kominami R; Inaba T; Honda H
Cancer Sci; 2009 Jul; 100(7):1219-26. PubMed ID: 19432895
[TBL] [Abstract][Full Text] [Related]
14. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
[TBL] [Abstract][Full Text] [Related]
15. Expression and tyrosine phosphorylation of Crk-associated substrate lymphocyte type (Cas-L) protein in human neutrophils.
Nakamoto T; Seo S; Sakai R; Kato T; Kutsuna H; Kurokawa M; Noda M; Miyasaka N; Kitagawa S
J Cell Biochem; 2008 Sep; 105(1):121-8. PubMed ID: 18465784
[TBL] [Abstract][Full Text] [Related]
16. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
Estrov Z; Talpaz M; Kantarjian HM; Zipf TF; McClain KL; Kurzrock R
Cancer Res; 1993 Jul; 53(14):3289-93. PubMed ID: 8324740
[TBL] [Abstract][Full Text] [Related]
18. Role of Dok-1 and Dok-2 in leukemia suppression.
Niki M; Di Cristofano A; Zhao M; Honda H; Hirai H; Van Aelst L; Cordon-Cardo C; Pandolfi PP
J Exp Med; 2004 Dec; 200(12):1689-95. PubMed ID: 15611295
[TBL] [Abstract][Full Text] [Related]
19. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl.
de Jong R; van Wijk A; Haataja L; Heisterkamp N; Groffen J
J Biol Chem; 1997 Dec; 272(51):32649-55. PubMed ID: 9405482
[TBL] [Abstract][Full Text] [Related]
20. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
